CA2868733C - Mesenchymal stem cells for treating inflammation - Google Patents

Mesenchymal stem cells for treating inflammation Download PDF

Info

Publication number: CA2868733C
Authority: CA; Canada
Prior art keywords: mesenchymal stem; stem cells; cells; use according; animal
Prior art date: 2004-03-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2868733A

Other languages

English (en)

French (fr)

Other versions

CA2868733A1 (en

Inventor

Mark F. Pittenger

Sudeepta Aggarwal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mesoblast International SARL

Original Assignee

Mesoblast International SARL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-22

Filing date

2005-03-15

Publication date

2019-12-17

2005-03-15 Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL

2005-03-15 Priority to CA2934682A priority Critical patent/CA2934682C/en

2005-03-15 Priority claimed from CA2564679A external-priority patent/CA2564679C/en

2005-10-06 Publication of CA2868733A1 publication Critical patent/CA2868733A1/en

2019-12-17 Application granted granted Critical

2019-12-17 Publication of CA2868733C publication Critical patent/CA2868733C/en

2025-03-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 322
206010061218 Inflammation Diseases 0.000 title claims abstract description 17
230000004054 inflammatory process Effects 0.000 title claims abstract description 17
210000004027 cell Anatomy 0.000 claims abstract description 102
241001465754 Metazoa Species 0.000 claims abstract description 75
238000004519 manufacturing process Methods 0.000 claims abstract description 14
210000004443 dendritic cell Anatomy 0.000 claims description 49
230000028327 secretion Effects 0.000 claims description 47
210000003289 regulatory T cell Anatomy 0.000 claims description 29
210000001744 T-lymphocyte Anatomy 0.000 claims description 27
102000003814 Interleukin-10 Human genes 0.000 claims description 19
108090000174 Interleukin-10 Proteins 0.000 claims description 19
230000000735 allogeneic effect Effects 0.000 claims description 14
230000001737 promoting effect Effects 0.000 claims description 12
230000004913 activation Effects 0.000 claims description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
210000002540 macrophage Anatomy 0.000 claims description 9
210000000440 neutrophil Anatomy 0.000 claims description 9
230000000770 proinflammatory effect Effects 0.000 claims description 9
208000024908 graft versus host disease Diseases 0.000 claims description 8
238000001990 intravenous administration Methods 0.000 claims description 7
239000006285 cell suspension Substances 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
210000000447 Th1 cell Anatomy 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
230000035800 maturation Effects 0.000 claims description 5
238000007910 systemic administration Methods 0.000 claims description 4
102100040247 Tumor necrosis factor Human genes 0.000 claims 1
238000000034 method Methods 0.000 abstract description 24
230000028993 immune response Effects 0.000 abstract description 7
230000001105 regulatory effect Effects 0.000 abstract description 4
230000008569 process Effects 0.000 abstract description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 57
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 29
229960002986 dinoprostone Drugs 0.000 description 27
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 27
230000033115 angiogenesis Effects 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
230000037361 pathway Effects 0.000 description 17
229940076144 interleukin-10 Drugs 0.000 description 15
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
241000124008 Mammalia Species 0.000 description 12
108010047620 Phytohemagglutinins Proteins 0.000 description 12
210000000822 natural killer cell Anatomy 0.000 description 12
230000001885 phytohemagglutinin Effects 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
102000004388 Interleukin-4 Human genes 0.000 description 11
108090000978 Interleukin-4 Proteins 0.000 description 11
201000010099 disease Diseases 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
208000023275 Autoimmune disease Diseases 0.000 description 10
230000001404 mediated effect Effects 0.000 description 10
238000011282 treatment Methods 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 9
208000026935 allergic disease Diseases 0.000 description 9
239000012228 culture supernatant Substances 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
206010016654 Fibrosis Diseases 0.000 description 8
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
230000004761 fibrosis Effects 0.000 description 8
206010052428 Wound Diseases 0.000 description 7
230000001464 adherent effect Effects 0.000 description 7
239000003937 drug carrier Substances 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
230000028709 inflammatory response Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
230000003993 interaction Effects 0.000 description 7
238000002955 isolation Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
101000958041 Homo sapiens Musculin Proteins 0.000 description 6
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 6
238000003501 co-culture Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
210000003162 effector t lymphocyte Anatomy 0.000 description 6
102000046949 human MSC Human genes 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
102000004889 Interleukin-6 Human genes 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
241000288906 Primates Species 0.000 description 5
230000003110 anti-inflammatory effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
102000006354 HLA-DR Antigens Human genes 0.000 description 4
108010058597 HLA-DR Antigens Proteins 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
230000003915 cell function Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
230000002519 immonomodulatory effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
108091033319 polynucleotide Proteins 0.000 description 4
102000040430 polynucleotide Human genes 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
102000003996 Interferon-beta Human genes 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
230000001745 anti-biotin effect Effects 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000000845 cartilage Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000002500 effect on skin Effects 0.000 description 3
230000032692 embryo implantation Effects 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000035876 healing Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229960001388 interferon-beta Drugs 0.000 description 3
238000001361 intraarterial administration Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
229920006008 lipopolysaccharide Polymers 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000011325 microbead Substances 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
231100000397 ulcer Toxicity 0.000 description 3
239000013598 vector Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
238000010600 3H thymidine incorporation assay Methods 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 2
102100022297 Integrin alpha-X Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000019552 anatomical structure morphogenesis Effects 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
201000005000 autoimmune gastritis Diseases 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
201000000523 end stage renal failure Diseases 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
210000004349 growth plate Anatomy 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
210000001821 langerhans cell Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000011164 ossification Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000003614 tolerogenic effect Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
208000031873 Animal Disease Models Diseases 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102000049320 CD36 Human genes 0.000 description 1
108010045374 CD36 Antigens Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
101800004490 Endothelin-1 Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
210000000712 G cell Anatomy 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000022461 Glomerular disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010019375 Helicobacter infections Diseases 0.000 description 1
208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100025306 Integrin alpha-IIb Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000013691 Interleukin-17 Human genes 0.000 description 1
108050003558 Interleukin-17 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010057168 Leishmania infections Diseases 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000002293 adipogenic effect Effects 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000011558 animal model by disease Methods 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000013459 approach Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010928 autoimmune thyroid disease Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000000981 bystander Effects 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
229940107200 chondroitin sulfates Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
231100000852 glomerular disease Toxicity 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000010410 layer Substances 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
210000003071 memory t lymphocyte Anatomy 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
208000030613 peripheral artery disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
239000002356 single layer Substances 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Developmental Biology & Embryology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA2868733A 2004-03-22 2005-03-15 Mesenchymal stem cells for treating inflammation Expired - Lifetime CA2868733C (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2934682A CA2934682C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US55511804P	2004-03-22	2004-03-22
US60/555,118		2004-03-22
CA2564679A CA2564679C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2564679A Division CA2564679C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2934682A Division CA2934682C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Publications (2)

Publication Number	Publication Date
CA2868733A1 CA2868733A1 (en)	2005-10-06
CA2868733C true CA2868733C (en)	2019-12-17

Family

ID=46060822

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CA2868733A Expired - Lifetime CA2868733C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells for treating inflammation
CA2934682A Expired - Lifetime CA2934682C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor
CA3135582A Pending CA3135582A1 (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CA2934682A Expired - Lifetime CA2934682C (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor
CA3135582A Pending CA3135582A1 (en)	2004-03-22	2005-03-15	Mesenchymal stem cells and uses therefor

Country Status (5)

Country	Link
JP (8)	JP6114500B2 (de)
AT (1)	ATE556134T1 (de)
CA (3)	CA2868733C (de)
ES (7)	ES2708627T3 (de)
TR (1)	TR201901268T4 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2708627T3 (es) *	2004-03-22	2019-04-10	Mesoblast Int Sarl	Células madre mesenquimales y sus usos
EP2298863B1 (de) *	2004-03-22	2015-07-22	Mesoblast International Sàrl	Mesenchymale Stammzellen und deren Verwendungen
WO2014098960A2 (en) *	2012-05-16	2014-06-26	The Johns Hopkins University	Stem cells as an individualized maternal therapy for prevention of prematurity
JP2016210730A (ja) *	2015-05-08	2016-12-15	上田　実	医薬組成物及びその製造方法並びに医薬品
CN109952371A (zh)	2016-11-15	2019-06-28	株式会社钟化	包含来自胎儿附属物的间充质系干细胞的细胞群、其制备方法、以及医药组合物
AU2018372631B2 (en)	2017-11-22	2025-06-05	Mesoblast International Sarl	Cellular compositions and methods of treatment I
WO2019132026A1 (ja)	2017-12-28	2019-07-04	株式会社カネカ	接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2020251020A1 (ja)	2019-06-14	2020-12-17	株式会社カネカ	間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
WO2021028583A1 (en) *	2019-08-15	2021-02-18	Nextcell Pharma Ab	Allogeneic composition for treatment of cns disorders
CN113813288B (zh) *	2021-08-11	2024-02-13	谢岩	间充质干细胞及包含其的组合物用于制备治疗烧伤难愈创面的药物的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0651641B2 (ja) *	1983-08-29	1994-07-06	株式会社ミドリ十字	ガンマ・インターフェロン組成物
JPH01501792A (ja) *	1986-03-17	1989-06-22	シェリング・コーポレーション	γ型インターフェロンによる癌の治療
EP0784482A2 (de) *	1994-06-07	1997-07-23	The Regents Of The University Of Minnesota	Methode zur inhibition der antigen spezifischen t-zellen immunantwort
CA2253724A1 (en) *	1996-04-26	1997-11-06	Case Western Reserve University	Skin regeneration using mesenchymal stem cells
ES2258329T3 (es) *	1998-03-18	2006-08-16	Osiris Therapeutics, Inc.	Celulas madre mesenquimaticas para la prevencion y tratamiento de respuestas inmunes en trasplantes.
US6368636B1 (en) *	1998-03-18	2002-04-09	Osiris Therapeutics, Inc.	Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
ES2205792T3 (es)	1998-04-03	2004-05-01	Osiris Therapeutics, Inc.	Celulas madre mesenquimatosas como inmunosupresores.
CN1307303C (zh) *	2000-01-19	2007-03-28	帕卡什·S·吉尔	针对反义vegf寡核苷酸的方法和组合物
ES2353061T5 (es) *	2000-04-25	2014-04-07	Osiris Therapeutics, Inc.	Reparación de articulaciones utilizando células madre mesenquimatosas
MXPA04007426A (es) *	2002-02-01	2004-10-11	Schering Corp	Usos de citosina de mamifero; reactivos relacionados.
JP3897343B2 (ja) *	2002-08-01	2007-03-22	株式会社林原生物化学研究所	免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
CA2547899C (en) *	2002-12-05	2014-04-15	Case Western Reserve University	Cell-based therapies for ischemia
ES2708627T3 (es) *	2004-03-22	2019-04-10	Mesoblast Int Sarl	Células madre mesenquimales y sus usos
EP2298863B1 (de) *	2004-03-22	2015-07-22	Mesoblast International Sàrl	Mesenchymale Stammzellen und deren Verwendungen

2005
- 2005-03-15 ES ES14172800T patent/ES2708627T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011226.7T patent/ES2645018T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011223.4T patent/ES2643030T3/es not_active Expired - Lifetime
- 2005-03-15 TR TR2019/01268T patent/TR201901268T4/tr unknown
- 2005-03-15 AT AT05725577T patent/ATE556134T1/de active
- 2005-03-15 ES ES05725577T patent/ES2385450T3/es not_active Expired - Lifetime
- 2005-03-15 CA CA2868733A patent/CA2868733C/en not_active Expired - Lifetime
- 2005-03-15 ES ES14172807T patent/ES2657382T5/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011224.2T patent/ES2643076T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011225.9T patent/ES2544689T3/es not_active Expired - Lifetime
- 2005-03-15 CA CA2934682A patent/CA2934682C/en not_active Expired - Lifetime
- 2005-03-15 CA CA3135582A patent/CA3135582A1/en active Pending
2012
- 2012-03-15 JP JP2012058539A patent/JP6114500B2/ja not_active Expired - Lifetime
2014
- 2014-11-28 JP JP2014241859A patent/JP5997237B2/ja not_active Expired - Lifetime
2017
- 2017-01-13 JP JP2017003854A patent/JP6382360B2/ja not_active Expired - Lifetime
- 2017-08-10 JP JP2017155229A patent/JP6757300B2/ja not_active Expired - Lifetime
2018
- 2018-10-09 JP JP2018190636A patent/JP6757383B2/ja not_active Expired - Lifetime
2020
- 2020-03-18 JP JP2020047240A patent/JP7033159B2/ja not_active Expired - Lifetime
2021
- 2021-08-30 JP JP2021140167A patent/JP7546239B2/ja not_active Expired - Lifetime
2023
- 2023-02-20 JP JP2023023996A patent/JP2023065486A/ja active Pending

Also Published As

Publication number	Publication date
CA2934682C (en)	2021-12-07
JP6382360B2 (ja)	2018-08-29
JP5997237B2 (ja)	2016-09-28
JP7033159B2 (ja)	2022-03-09
ES2643030T3 (es)	2017-11-21
JP2015061862A (ja)	2015-04-02
JP2020111591A (ja)	2020-07-27
ES2544689T3 (es)	2015-09-02
HK1205531A1 (en)	2015-12-18
ES2385450T3 (es)	2012-07-25
ES2708627T3 (es)	2019-04-10
ATE556134T1 (de)	2012-05-15
ES2643076T3 (es)	2017-11-21
JP2019014747A (ja)	2019-01-31
JP6114500B2 (ja)	2017-04-12
TR201901268T4 (tr)	2019-02-21
ES2657382T5 (es)	2021-07-12
JP7546239B2 (ja)	2024-09-06
ES2645018T3 (es)	2017-12-01
CA3135582A1 (en)	2005-10-06
JP2012176948A (ja)	2012-09-13
JP6757300B2 (ja)	2020-09-16
HK1205677A1 (en)	2015-12-24
JP2023065486A (ja)	2023-05-12
ES2657382T3 (es)	2018-03-05
CA2934682A1 (en)	2005-10-06
JP2021191771A (ja)	2021-12-16
CA2868733A1 (en)	2005-10-06
JP6757383B2 (ja)	2020-09-16
JP2017080507A (ja)	2017-05-18
JP2018009002A (ja)	2018-01-18

Legal Events

Date	Code	Title	Description
2014-11-27	EEER	Examination request	Effective date: 20141029

Publication	Publication Date	Title
EP2824174B1 (de)	2018-11-28	Mesenchymale stammzellen und verwendungen dafür
JP2023065486A (ja)	2023-05-12	間葉幹細胞及びその使用法
AU2012205269B2 (en)	2015-08-27	Mesenchymal stem cells and uses therefor
AU2020201636B2 (en)	2023-04-13	Mesenchymal stem cells and uses therefor
HK1262056A1 (en)	2020-01-10	Mesenchymal stem cells and uses therefor
HK1205531B (en)	2019-09-13	Mesenchymal stem cells and uses therefor